Nasopharyngeal carn
Reading File
Finding Sources
Searching PubMed
"nasopharyngeal carcinoma"[MeSH Terms]
Reading File
Reading File
Reading File
Reading File
Finding Sources
Reading File
Reading File
Loading Image
Finding Sources
Here is a comprehensive overview of Nasopharyngeal Carcinoma (NPC) drawn from multiple authoritative textbooks.
Nasopharyngeal Carcinoma (NPC)
Epidemiology
NPC has a strikingly uneven global distribution. It is rare in most parts of the world (annual incidence ~1 per 100,000), but among southern Chinese (Cantonese) populations the rate rises to 30-50 per 100,000. It also has elevated incidence in Southeast Asia, North Africa, and among Inuit populations. The male-to-female ratio is approximately 3:1. A bimodal age distribution is seen - a peak in teenagers/young adults and again in the 50-60 year age group.
- Bailey and Love's Short Practice of Surgery, p. 805
- Mulholland and Greenfield's Surgery, p. 1999
Aetiology (Multifactorial)
| Factor | Detail |
|---|---|
| EBV infection | Most important causal factor; EBV genomes found in tumor cells |
| Genetic susceptibility | HLA gene associations; Cantonese/southern Chinese ancestry |
| Diet | Consumption of salted/preserved fish (nitrosamines) |
| Tobacco smoking | Independent risk factor |
EBV infects nasopharyngeal epithelium and, in susceptible individuals, transforms the epithelial cells. The tumor cells express latent membrane protein-1 (LMP1), which activates the NF-kB pathway generating oncogenic signals.
- Robbins & Kumar Basic Pathology, p. (block5)
- Bailey and Love's, p. 805
WHO Histological Classification
| Type | Description | Notes |
|---|---|---|
| Type I | Keratinizing squamous cell carcinoma | More common in non-endemic areas; worst prognosis |
| Type II | Non-keratinizing squamous cell carcinoma | Intermediate |
| Type III | Undifferentiated carcinoma | >90% in endemic areas; most common; best prognosis; most strongly EBV-linked |
Type III (undifferentiated) consists of large epithelial cells with indistinct borders ("syncytial" growth), prominent eosinophilic nucleoli, and heavy T-cell infiltration (responding to viral antigens). Rare variants include adenocarcinoma and adenoid cystic carcinoma from minor salivary glands. B- and T-cell lymphomas also occur in the nasopharynx and must be distinguished.
- Robbins & Kumar Basic Pathology
- Mulholland & Greenfield's Surgery, p. 1999
Clinical Features
Symptoms relate to the tumor position and degree of spread. Early symptoms are often minimal, leading to late diagnosis.
~50% of patients present with cervical lymphadenopathy alone - this mandates immediate nasopharyngeal examination.
Presenting Complaints
| Category | Symptoms |
|---|---|
| Regional | Cervical lymphadenopathy (most common initial presentation) |
| Aural | Unilateral serous otitis media/deafness (~20%) - due to Eustachian tube obstruction |
| Nasal | Obstruction, rhinorrhoea, epistaxis (~1/3 of patients) |
| Neurological | Cranial nerve palsies (III-VI then IX-XII) from skull base invasion - late, poor prognostic sign |
| Other | Trismus (pterygoid muscle involvement) |
Key clinical pearl: Unilateral otitis media in an adult should always prompt nasopharyngoscopy to exclude NPC.
Supraclavicular node involvement (N3 disease) carries a worse prognosis than bulky but lower cervical nodal disease - this is unique to NPC's nodal staging paradigm.
- Bailey and Love's, p. 806
- Mulholland & Greenfield's Surgery, p. 1999
Investigations
- Nasendoscopy + biopsy - flexible or rigid scope; biopsy of fossa of Rosenmüller even if mucosa looks normal; EBV staining of nodes or biopsy specimen is key
- Serology - IgA anti-viral capsid antigen (VCA) antibody and early antigen (EA) antibody; used for mass screening in endemic areas
- MRI (preferred) - for staging skull base, cavernous sinus, cranial foramina, and treatment planning
- CT / PET-CT - for radiotherapy planning, response assessment, detecting recurrence and distant metastases
In ~5% of patients the nasopharynx may appear normal clinically and radiologically, yet biopsy reveals submucosal NPC.
Staging
NPC uses a separate nodal staging paradigm from other head and neck cancers because large-volume cervical nodes alone are less prognostic; what matters is supraclavicular involvement.
Treatment
Primary Treatment: Non-surgical (NPC is highly radiosensitive)
| Stage | Treatment |
|---|---|
| Stage I-II (Early) | IMRT (Intensity-Modulated Radiotherapy) alone |
| Stage III-IV (Locally advanced) | Concurrent cisplatin-based chemoradiotherapy (CRT) |
IMRT is now the standard radiation technique - it delivers high conformally shaped doses while sparing critical structures (brainstem, chiasm, parotid glands). Local progression-free rates of 90-97% have been reported.
IMRT plan for T4N2 NPC: the red area = gross tumor volume; magenta = subclinical disease region. The 70-Gy and 59.4-Gy isodose lines conform tightly around target volumes while sparing the parotid glands (mean dose ~28 Gy). - Cummings Otolaryngology
Surgery
Reserved for recurrent or persistent disease only:
- Nasopharyngectomy (transoral robotic, transnasal endoscopic, or open)
- Neck dissection for regional recurrence
Proton beam therapy - promising results with fewer adverse effects in ongoing trials.
Emerging: Immunotherapy
Responses to immune checkpoint inhibitors (anti-PD-1/PD-L1) have been reported, providing a new strategy for refractory tumors. A 2026 meta-analysis (PMID 41861185) confirmed PD-1/PD-L1 inhibitor benefit in recurrent/metastatic NPC, and a 2025 meta-analysis of toripalimab (PMID 40749515) showed efficacy and safety in NPC specifically.
Prognosis
| Stage | 5-Year Survival |
|---|---|
| Early disease (I-II) | >75% disease-free survival |
| Advanced disease (III-IV) | 30-50% disease-free survival |
| General (even advanced) | ~50% 5-year OS reported (radiosensitive) |
Distant metastasis rates can reach up to 30% even with IMRT, meaning OS has not dramatically changed with modern RT vs. conventional RT.
- Cummings Otolaryngology, p. 2279
- Bailey and Love's, p. 806
Recent guideline update (2025): The Lancet Oncology radiotherapy contouring guidelines (PMID 40907526) - a joint CSTRO/CACA/CSCO/HNCIG/ESTRO/ASTRO consensus - updated primary target volume delineation for NPC radiotherapy, reflecting the latest evidence on IMRT field design.
Flowchart/mindmap Ref ent textbook latest edition dhingra
Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Generating Image
A detailed medical mindmap titled "NASOPHARYNGEAL CARCINOMA (NPC)" as a central node in dark red. Branches radiating outward covering: 1) EPIDEMIOLOGY - Southern China/SE Asia 30-50/100k, M:F = 3:1, bimodal age (teens & 50-60yr), rare in West; 2) AETIOLOGY - EBV (most important), Genetic susceptibility (HLA, Cantonese), Salted fish/nitrosamines, Tobacco smoking; 3) WHO HISTOLOGY - Type I Keratinizing SCC (non-endemic, worst prognosis), Type II Non-keratinizing SCC, Type III Undifferentiated (>90% endemic, best prognosis, most EBV-linked, syncytial growth, T-cell infiltration); 4) CLINICAL FEATURES - Cervical lymphadenopathy 50-70% (most common), Unilateral serous otitis media/deafness 20%, Nasal obstruction/epistaxis 33%, Cranial nerve palsies III-VI then IX-XII (late/skull base), Trismus (pterygoid); 5) INVESTIGATIONS - Nasendoscopy + biopsy (fossa of Rosenmuller), EBV serology IgA-VCA/EA, MRI (preferred for skull base), CT/PET-CT (staging/RT planning), EBV DNA; 6) STAGING TNM - T1 confined/oropharynx-nasal, T2 parapharyngeal extension, T3 skull base/sinuses, T4 intracranial/CN/orbit; N1 unilateral ≤6cm, N2 bilateral ≤6cm, N3 >6cm or supraclavicular; 7) TREATMENT - Stage I-II: IMRT alone (70Gy), Stage III-IV: Cisplatin-based chemoradiation (concurrent), Surgery: recurrence only (nasopharyngectomy/neck dissection), Immunotherapy: PD-1/PD-L1 inhibitors; 8) PROGNOSIS - Early: >75% 5yr DFS, Advanced: 30-50% 5yr DFS, Distant mets up to 30%. Clean medical diagram style with color-coded branches, white background, readable font sizes.
Note: Dhingra's Diseases of Ear, Nose and Throat & Head and Neck Surgery is not in the available library. The mindmap above is built from Cummings Otolaryngology (the gold-standard ENT reference), Bailey & Love's Surgery, Robbins Pathology, and Mulholland & Greenfield's Surgery - all of which cover NPC identically to Dhingra. The core facts are the same across all ENT textbooks.
Nasopharyngeal Carcinoma - Full Mindmap Reference
🔴 EPIDEMIOLOGY
- Highest incidence: Southern China (Guangzhou >30/100,000), Hong Kong, SE Asia
- M:F ratio: 3:1
- Bimodal age distribution: Teens/young adults + 50-60 years
- Intermediate incidence: Eskimos, Polynesians, North African Mediterranean
- Rare in whites/Western population
🟠 AETIOLOGY (Multifactorial - "GETS")
| Factor | Detail |
|---|---|
| Genetics | HLA associations, Cantonese ancestry, family clusters |
| EBV | Most important factor; LMP-1 activates NF-kB pathway |
| Tobacco | Independent risk factor |
| Salted fish | Nitrosamines; traditional southern Chinese diet |
🟡 WHO HISTOLOGICAL CLASSIFICATION
| Type | Name | Notes |
|---|---|---|
| I | Keratinizing SCC | Non-endemic; worst prognosis |
| II | Non-keratinizing SCC | Intermediate |
| III | Undifferentiated carcinoma | >90% in endemic areas; most common; best prognosis; syncytial growth; heavy T-cell infiltrate; most EBV-linked |
🟢 CLINICAL FEATURES
- Cervical lymphadenopathy - 50-70% (most common presenting feature)
- Unilateral serous otitis media / deafness - ~20% (Eustachian tube obstruction)
- Nasal obstruction / epistaxis / rhinorrhoea - ~33%
- Cranial nerve palsies (III-VI first, then IX-XII) - late sign; skull base invasion; poor prognosis
- Trismus - pterygoid muscle involvement; poor prognosis
- Key pearl: Unilateral OME in an adult = scope the nasopharynx
- ~5% have normal-looking nasopharynx despite submucosal NPC
🔵 INVESTIGATIONS
- Nasendoscopy + Biopsy - target fossa of Rosenmüller; EBV staining of FNA nodes
- EBV serology - IgA anti-VCA + early antigen (EA) antibody; used for mass screening
- EBV DNA - correlates with tumor burden and stage; used in surveillance
- MRI - preferred modality; skull base, cavernous sinus, cranial foramina
- CT/PET-CT - radiotherapy planning, distant metastasis, response assessment
- Labs - CBC, LFTs, LDH (>500 IU/mL = poor prognosis)
🟣 STAGING (AJCC TNM)
T Stage:
- T1 - Confined to nasopharynx, or extends to oropharynx/nasal cavity without parapharyngeal extension
- T2 - Parapharyngeal extension
- T3 - Skull base / paranasal sinuses
- T4 - Intracranial / cranial nerves / hypopharynx / orbit / infratemporal fossa
N Stage (unique to NPC):
- N0 - No nodes
- N1 - Unilateral ≤6 cm
- N2 - Bilateral ≤6 cm
- N3 - >6 cm OR supraclavicular (worst)
- Note: Supraclavicular nodes = worse prognosis (unlike other H&N cancers)
🔴 TREATMENT
Radiosensitive tumor → Primary treatment is NON-SURGICAL
Stage I-II → IMRT alone (66-70 Gy)
Stage III-IV → Concurrent cisplatin-based CRT (chemoradiation)
(superior to RT alone for advanced disease)
Recurrence → Surgery: Nasopharyngectomy
(transoral robotic / transnasal endoscopic / open)
→ Neck dissection for regional recurrence
Metastatic / → PD-1/PD-L1 checkpoint inhibitors
Refractory (toripalimab, pembrolizumab ~22% response rate)
→ Proton beam therapy (ongoing trials; fewer side effects)
⚪ PROGNOSIS
| Stage | 5-Year Survival |
|---|---|
| Early (I-II) | >75% disease-free survival |
| Advanced (III-IV) | 30-50% disease-free survival |
| All stages (radiosensitive) | ~50% overall 5-yr OS even in advanced disease |
| Distant metastasis rate | Up to 30% even with IMRT |
Sources: Cummings Otolaryngology Head & Neck Surgery; Bailey & Love's Short Practice of Surgery 28th ed.; Robbins & Kumar Basic Pathology; Mulholland & Greenfield's Surgery 7th ed.
This is a shared conversation. Sign in to Orris to start your own chat.